IDO inhibitors might work as single agents if IDO expression in the tumor microenvironment is the rate-limiting step and there are no other barriers to antitumor immune response, such as inadequate priming of the immune system, i.e., a lack of CD8+ T cells at the tumor site. This evidence concerns the gene CD8A and neoplasm.